...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Leukemia and lymphoma >Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxide
【24h】

Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxide

机译：全反式维甲酸加化学疗法或全反式维甲酸加三氧化二砷治疗的急性早幼粒细胞白血病继发性肿瘤的发生率

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The incidence and pattern of secondary neoplasms in patients with acute promyelocytic leukemia (APL) treated with all-trans retinoic acid (ATRA)-containing regimens is not well described. We compared 160 patients with APL treated with ATRA plus idarubicin (n = 54) or ATRA plus arsenic trioxide (ATO) (n = 106) for the incidence of secondary cancers per unit time of follow-up. Median follow-up times for the two cohorts were 136 and 29 months, respectively. Nine patients developed secondary cancers in the chemotherapy group. These included two breast cancers, three myelodysplastic syndromes/acute myeloid leukemia, one vulvar cancer, one prostate cancer, one colon cancer and one soft tissue sarcoma. A melanoma and one pancreatic cancer developed in the ATO group. We conclude that treatment of patients with APL using the non-chemotherapy regimen of ATRA plus ATO is not associated with a higher incidence of secondary cancers (p = 0.29) adjusted for unit time of exposure.
机译：含全反式维甲酸（ATRA）的方案治疗的急性早幼粒细胞白血病（APL）患者继发性肿瘤的发生率和模式没有得到很好的描述。我们比较了160例接受ATRA加伊达比星（n = 54）或ATRA加三氧化二砷（ATO）（n = 106）治疗的APL患者每单位随访时间继发癌症的发生率。这两个队列的中位随访时间分别为136个月和29个月。化疗组中有9名患者发生了继发性癌症。这些疾病包括两种乳腺癌，三种骨髓增生异常综合症/急性髓性白血病，一种外阴癌，一种前列腺癌，一种结肠癌和一种软组织肉瘤。 ATO组发生了黑色素瘤和一种胰腺癌。我们得出的结论是，使用ATRA加ATO的非化学疗法治疗APL患者与单位暴露时间调整的继发性癌症发生率更高（p = 0.29）无关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号